Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MERRILL K SHUM

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1982819702
CMS profile
90154
Location
WHITTIER, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$6,659.04

258 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $6,200.39 252
Long term medical supply or device loan $282.73 3
Education $175.92 3

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
PFIZER INC. $570.36 23
Novartis Pharmaceuticals Corporation $519.48 15
Janssen Biotech, Inc. $368.27 19
AstraZeneca Pharmaceuticals LP $325.39 12
Eisai Inc. $305.55 10
Gilead Sciences, Inc. $252.11 14
Merck Sharp & Dohme LLC $246.78 10
Incyte Corporation $225.80 9
Exelixis Inc. $219.10 7
Ipsen Biopharmaceuticals, Inc $202.76 6
ABBVIE INC. $174.79 9
GENZYME CORPORATION $153.85 7
Daiichi Sankyo Inc. $134.17 5
PROGENICS PHARMACEUTICALS, INC. $123.27 2
Takeda Pharmaceuticals U.S.A., Inc. $115.75 5
Celgene Corporation $108.74 4
SOBI, INC $107.79 4
Novocure Inc. $101.19 3
Boehringer Ingelheim Pharmaceuticals, Inc. $99.69 4
Stemline Therapeutics Inc. $95.41 3
Bayer Healthcare Pharmaceuticals Inc. $92.60 4
Alexion Pharmaceuticals, Inc. $90.03 3
SERVIER PHARMACEUTICALS LLC $89.61 3
PharmaEssentia USA Corporation $89.13 3
ADC THERAPEUTICS AMERICA, INC. $83.54 3
GlaxoSmithKline, LLC. $73.69 3
BeiGene USA, Inc. $72.30 2
Amgen Inc. $65.91 3
BeOne Medicines USA, Inc. $64.85 3
Genmab U.S., Inc. $61.74 2
PUMA BIOTECHNOLOGY, INC. $59.94 3
Karyopharm Therapeutics Inc. $59.66 2
Adaptive Biotechnologies Corporation $58.86 3
E.R. Squibb & Sons, L.L.C. $57.36 3
Apellis Pharmaceuticals, Inc. $56.99 2
ARRAY BIOPHARMA INC $54.65 2
Octapharma USA, Inc. $54.24 2
Lilly USA, LLC $52.70 2
Aveo Pharmaceuticals, Inc. $51.24 2
TAIHO ONCOLOGY, INC. $49.97 2
Kite Pharma, Inc. $48.04 2
Coherus Oncology, Inc. $46.15 2
Deciphera Pharmaceuticals Inc. $46.10 2
Boston Scientific Corporation $42.67 1
Spectrum Pharmaceuticals Inc. $41.85 1
Rigel Pharmaceuticals, Inc. $37.84 2
JAZZ PHARMACEUTICALS INC. $37.72 2
EMD Serono, Inc. $37.42 1
Astellas Pharma US Inc $37.00 2
Invivyd Inc $34.33 1
Geron Corporation $34.11 1
Agios Pharmaceuticals, Inc. $32.36 1
Corcept Therapeutics $30.81 1
Pharmacosmos Therapeutics Inc. $30.54 1
Genentech USA, Inc. $29.46 1
Legend Biotech USA Inc. $28.41 1
Secura Bio, Inc. $26.25 1
Dendreon Pharmaceuticals LLC $25.35 1
Tempus AI, Inc $24.35 1
Azurity Pharmaceuticals, Inc. $23.77 1
Iovance Biotherapeutics, Inc. $23.20 1
Blueprint Medicines Corporation $22.68 1
Caris MPI, Inc. $22.32 1
Sumitomo Pharma America, Inc. $22.20 1
Verity Pharmaceuticals Inc. $17.45 1
GE HEALTHCARE $17.41 1
Telix Pharmaceuticals $17.26 1
Chiesi USA, Inc. $17.10 1
SpringWorks Therapeutics, Inc. $15.63 1

Page 4 of 6; records 151–200 of 258 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MERRILL K SHUM

NPI 1982819702 · CMS profile ID 90154

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

WHITTIER, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 4 of 6; records 151–200 of 258 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1982819702?year=2025&recipient=provider&page=4#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MERRILL K SHUM, NPI 1982819702, CMS profile ID 90154. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 6; records 151–200 of 258 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1982819702?year=2025&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). MERRILL K SHUM, NPI 1982819702, CMS profile ID 90154. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 6; records 151–200 of 258 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1982819702?year=2025&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
MERRILL K SHUM, NPI 1982819702, CMS profile ID 90154, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 6; records 151–200 of 258 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1982819702?year=2025&recipient=provider&page=4#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

258 matching records · $6,659.04 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 258 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 151–200 of 258.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Incyte Corporation $25.5805/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1226121829 CMS
Gilead Sciences, Inc. $11.9305/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234583262 CMS
PFIZER INC. $37.3905/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1229664390 CMS
Novartis Pharmaceuticals Corporation $12.7505/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200491582 CMS
Janssen Biotech, Inc. $16.4405/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174882727 CMS
Merck Sharp & Dohme LLC $24.9005/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238044733 CMS
Invivyd Inc $34.3305/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1240487934 CMS
Novartis Pharmaceuticals Corporation $2.0105/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200491564 CMS
Novartis Pharmaceuticals Corporation $24.9605/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200491566 CMS
Rigel Pharmaceuticals, Inc. $22.7405/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1247373647 CMS
Novocure Inc. $37.3005/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1251151847 CMS
Exelixis Inc. $14.5005/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1218798953 CMS
Janssen Biotech, Inc. $11.4305/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174881605 CMS
Novartis Pharmaceuticals Corporation $32.9005/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200491578 CMS
Merck Sharp & Dohme LLC $26.3905/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238320776 CMS
GENZYME CORPORATION $12.6905/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233407791 CMS
Lilly USA, LLC $18.8905/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186759687 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $22.5505/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223019868 CMS
Janssen Biotech, Inc. $4.3205/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174883149 CMS
Aveo Pharmaceuticals, Inc. $28.5005/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1199898722 CMS
PFIZER INC. $9.9104/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1231301411 CMS
Stemline Therapeutics Inc. $29.7604/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244099497 CMS
ABBVIE INC. $24.3704/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204276229 CMS
PFIZER INC. $122.7604/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1231605486 CMS
Eisai Inc. $28.9204/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244498241 CMS
Boston Scientific Corporation $42.6704/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1181439590 CMS
ABBVIE INC. $7.1104/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204276225 CMS
Exelixis Inc. $34.4004/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1218798955 CMS
AstraZeneca Pharmaceuticals LP $33.0304/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1207093233 CMS
Gilead Sciences, Inc. $12.8904/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234581486 CMS
AstraZeneca Pharmaceuticals LP $24.4504/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206954142 CMS
Merck Sharp & Dohme LLC $25.2504/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238183161 CMS
Novartis Pharmaceuticals Corporation $5.1604/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200491576 CMS
AstraZeneca Pharmaceuticals LP $11.6704/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206261853 CMS
ADC THERAPEUTICS AMERICA, INC. $34.0804/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1246128352 CMS
E.R. Squibb & Sons, L.L.C. $21.7104/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184941371 CMS
Octapharma USA, Inc. $35.5304/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1245083543 CMS
PFIZER INC. $6.8904/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228839114 CMS
Janssen Biotech, Inc. $6.2204/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174882325 CMS
Janssen Biotech, Inc. $33.2504/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174883478 CMS
Novartis Pharmaceuticals Corporation $34.2404/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200491562 CMS
Tempus AI, Inc $24.3504/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1250351818 CMS
Gilead Sciences, Inc. $10.4704/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234585864 CMS
Karyopharm Therapeutics Inc. $30.0804/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1246648993 CMS
Daiichi Sankyo Inc. $24.1404/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1197054573 CMS
SOBI, INC $32.1904/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1240288703 CMS
Janssen Biotech, Inc. $21.6003/31/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174882904 CMS
PFIZER INC. $22.8503/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1229656825 CMS
Eisai Inc. $31.6303/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244498239 CMS
Novartis Pharmaceuticals Corporation $83.3303/26/2025 Long term medical supply or device loan No dispute reported Delay: No
Change: NEW
06/30/2026 1200491538 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $3,302.02 154
PY2020 $13,851.53 162
PY2021 $6,705.73 184
PY2022 $9,354.03 231
PY2023 $9,632.06 231
PY2024 $16,544.77 283
PY2025 $6,659.04 258

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $2,326.60 12
PY2024 Principal investigator $183,196.82 12
PY2023 Principal investigator $105,385.99 35
PY2022 Principal investigator $72,151.47 11
PY2021 Principal investigator $254,040.30 58
PY2020 Principal investigator $366,072.31 61
PY2019 Recipient $108.40 1
PY2019 Principal investigator $536,478.32 141

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

12 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $67.50 11/21/2025 Non-covered Recipient Entity
HELIOS CR INC
A RANDOMIZED, OPEN-LABEL, C5 INHIBITOR-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF POZELIMAB AND CEMDISIRAN COMBINATION THERAPY IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA WHO ARE COMPLEMENT INHIBITOR TREATMENT-NAIVE OR HAVE NOT RECENTLY RECEIVED COMPLEMENT INHIBITOR THERAPY No dispute reported 06/30/2026 1184263797
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $330.75 11/21/2025 Non-covered Recipient Entity
HELIOS CR INC
A RANDOMIZED, OPEN-LABEL, C5 INHIBITOR-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF POZELIMAB AND CEMDISIRAN COMBINATION THERAPY IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA WHO ARE COMPLEMENT INHIBITOR TREATMENT-NAIVE OR HAVE NOT RECENTLY RECEIVED COMPLEMENT INHIBITOR THERAPY No dispute reported 06/30/2026 1184263799
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $67.50 11/21/2025 Non-covered Recipient Entity
HELIOS CR INC
A RANDOMIZED, OPEN-LABEL, C5 INHIBITOR-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF POZELIMAB AND CEMDISIRAN COMBINATION THERAPY IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA WHO ARE COMPLEMENT INHIBITOR TREATMENT-NAIVE OR HAVE NOT RECENTLY RECEIVED COMPLEMENT INHIBITOR THERAPY No dispute reported 06/30/2026 1184263801
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $87.75 11/21/2025 Non-covered Recipient Entity
HELIOS CR INC
A RANDOMIZED, OPEN-LABEL, C5 INHIBITOR-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF POZELIMAB AND CEMDISIRAN COMBINATION THERAPY IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA WHO ARE COMPLEMENT INHIBITOR TREATMENT-NAIVE OR HAVE NOT RECENTLY RECEIVED COMPLEMENT INHIBITOR THERAPY No dispute reported 06/30/2026 1184263803
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.25 11/21/2025 Non-covered Recipient Entity
HELIOS CR INC
A RANDOMIZED, OPEN-LABEL, C5 INHIBITOR-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF POZELIMAB AND CEMDISIRAN COMBINATION THERAPY IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA WHO ARE COMPLEMENT INHIBITOR TREATMENT-NAIVE OR HAVE NOT RECENTLY RECEIVED COMPLEMENT INHIBITOR THERAPY No dispute reported 06/30/2026 1184263805
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $101.25 11/21/2025 Non-covered Recipient Entity
HELIOS CR INC
A RANDOMIZED, OPEN-LABEL, C5 INHIBITOR-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF POZELIMAB AND CEMDISIRAN COMBINATION THERAPY IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA WHO ARE COMPLEMENT INHIBITOR TREATMENT-NAIVE OR HAVE NOT RECENTLY RECEIVED COMPLEMENT INHIBITOR THERAPY No dispute reported 06/30/2026 1184263807
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $405.00 11/20/2025 Non-covered Recipient Entity
HELIOS CR INC
A RANDOMIZED, OPEN-LABEL, C5 INHIBITOR-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF POZELIMAB AND CEMDISIRAN COMBINATION THERAPY IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA WHO ARE COMPLEMENT INHIBITOR TREATMENT-NAIVE OR HAVE NOT RECENTLY RECEIVED COMPLEMENT INHIBITOR THERAPY No dispute reported 06/30/2026 1184263065
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 11/20/2025 Non-covered Recipient Entity
HELIOS CR INC
A RANDOMIZED, OPEN-LABEL, C5 INHIBITOR-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF POZELIMAB AND CEMDISIRAN COMBINATION THERAPY IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA WHO ARE COMPLEMENT INHIBITOR TREATMENT-NAIVE OR HAVE NOT RECENTLY RECEIVED COMPLEMENT INHIBITOR THERAPY No dispute reported 06/30/2026 1184263067
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $250.00 10/30/2025 Non-covered Recipient Entity
HELIOS CR INC
A RANDOMIZED, OPEN-LABEL, C5 INHIBITOR-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF POZELIMAB AND CEMDISIRAN COMBINATION THERAPY IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA WHO ARE COMPLEMENT INHIBITOR TREATMENT-NAIVE OR HAVE NOT RECENTLY RECEIVED COMPLEMENT INHIBITOR THERAPY No dispute reported 06/30/2026 1184255789
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $250.00 10/29/2025 Non-covered Recipient Entity
HELIOS CR INC
A RANDOMIZED, OPEN-LABEL, C5 INHIBITOR-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF POZELIMAB AND CEMDISIRAN COMBINATION THERAPY IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA WHO ARE COMPLEMENT INHIBITOR TREATMENT-NAIVE OR HAVE NOT RECENTLY RECEIVED COMPLEMENT INHIBITOR THERAPY No dispute reported 06/30/2026 1184254345
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $250.00 10/09/2025 Non-covered Recipient Entity
HELIOS CR INC
A RANDOMIZED, OPEN-LABEL, C5 INHIBITOR-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF POZELIMAB AND CEMDISIRAN COMBINATION THERAPY IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA WHO ARE COMPLEMENT INHIBITOR TREATMENT-NAIVE OR HAVE NOT RECENTLY RECEIVED COMPLEMENT INHIBITOR THERAPY No dispute reported 06/30/2026 1184249322
Principal investigator 1 AstraZeneca Pharmaceuticals LP $10.60 01/09/2025 Non-covered Recipient Entity
THE ONCOLOGY INSTITUTE OF HOPE AND INNOVATION
A Phase 1b, Multicenter, 2-Part, Open-Label Study of Datopotamab Deruxtecan (Dato-DXd) in Combination with Durvalumab with or without Carboplatinin Subjects with Advanced or Metastatic Non-Small Cell Lung Cancer (Tropion-Lung04) No dispute reported 06/30/2026 1185550604